生命科学资讯

GSK walks away from remaining Ideaya programs

Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay

FDA misses PDUFA review deadline for Agios' thalassemia drug

Other news to note for Dec. 8, 2025

Regulatory actions for Dec. 8, 2025

Viatris monetizes equity stake in Biocon, gets $400M cash

GSK goes away, Ideaya synthetic lethality bids in-house again

Mirum adds to rare live disease portfolio with $820M Bluejay buy

Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for approval

Stryker promotes new president, COO to help lead its M&A strategy

Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M

Wave, Structure stocks double on obesity data readouts

Dyne readies FDA push after DMD exon 51 med excels in trial

Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets

Cogent’s mastocytosis drug continues momentum, helps treat sicker patients

Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC

#ASH25: Kura, Syndax detail data for rival menin inhibitors as both eye earlier use in AML

Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar

ASH 2025: Speeding AML research with MRD surrogate endpoint

Med-tech gainers and losers for Dec. 1-5, 2025